Syros Pharmaceuticals, Inc. (SYRS)
After hours:
| Previous close | 5.14 |
| Open | 5.20 |
| Bid | 5.04 x 100 |
| Ask | 5.09 x 100 |
| Day's range | 5.00 - 5.20 |
| 52-week range | 2.09 - 8.17 |
| Volume | |
| Avg. volume | 212,504 |
| Market cap | 135.973M |
| Beta (5Y monthly) | 1.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
CAMBRIDGE, Mass., April 09, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression as detected by an FDA approved test
- Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 02, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a restricted stock unit (RSU) award for 8,400 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros. This RSU was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
- Business Wire
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
CAMBRIDGE, Mass., March 27, 2024--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.
